fluorouracil has been researched along with Hormone-Dependent Neoplasms in 71 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined if inclusion of a taxane and more prolonged preoperative chemotherapy improves pathologic complete response (pCR) rate in estrogen receptor (ER)-positive breast cancer compared with three to four courses of 5-fluorouracil, doxorubicin, cyclophosphamide (FAC)." | 10.22 | Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. ( Anderson, K; Andre, F; Buchholz, TA; Buzdar, AU; Frye, D; Gonzalez-Angulo, AM; Hess, KR; Hortobagyi, GN; Kau, SW; Kuerer, HM; Mazouni, C; Pusztai, L; Symmans, WF, 2007) |
| "The purpose of this study was to determine the relative efficacy of doxorubicin versus methotrexate in combination with intravenous cyclophosphamide and 5-fluorouracil (FAC versus CMF) as adjuvant chemotherapy for operable breast cancer." | 10.20 | Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a ( Albanell, J; Aranda, J; Campbell, J; Camps, C; Candel, MT; Carrato, A; Casado, A; Diaz-Rubio, E; Gonzalez, R; Lizon, J; Martin, M; Massuti, B; Munarriz, B; Sole-Calvo, A; Villar, A, 2003) |
| "Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies." | 9.15 | Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. ( Chen, DR; Chen, ST; Hsieh, CM; Huang, CS; Kuo, SH; Lu, YS; Tseng, LM; Wang, HC; Yeh, DC; Yeh, HT, 2011) |
| "In the International Breast Cancer Study Group (IBCSG) trial VII, 1212 postmenopausal patients with node-positive disease were randomized to receive tamoxifen for 5 years or tamoxifen plus three concurrent courses of cyclophosphamide, methotrexate and 5-fluorouracil ('classical' CMF) chemotherapy, either early, delayed or both." | 9.11 | Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Collins, J; Crivellari, D; Erzen, D; Forbes, J; Gelber, RD; Goldhirsch, A; Holmberg, S; Li, S; Lindtner, J; Murray, E; Pagani, O; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B; Veronesi, A, 2005) |
| "To compare the efficacy of chemotherapy versus that of tamoxifen plus ovarian suppression in pre-/perimenopausal estrogen receptor-positive patients with early breast cancer." | 9.09 | Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomi ( Aldrighetti, D; Amoroso, D; Boccardo, F; Bolognesi, A; Distante, V; Farris, A; Genta, F; Giai, M; Mesiti, M; Pacini, P; Romeo, D; Rubagotti, A; Sismondi, P, 2000) |
| "Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide." | 9.07 | Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study. ( Coltman, CA; Ellis, GK; Green, S; Hynes, HE; Livingston, RB; Rivkin, S; Schulman, S, 1991) |
| "Eighty-nine postmenopausal women with metastatic breast cancer, in whom estrogen receptors (ER) were positive or unknown, were treated on a controlled trial to determine the effectiveness of tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders." | 9.05 | Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial. ( Brodovsky, H; Catalano, RB; Creech, RH; Glick, JH; Holroyde, C; Torri, S; Varano, M, 1980) |
| " Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy." | 8.85 | Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. ( Guarneri, V, 2009) |
| "Our previous study indicated that concurrent administration of 4-OH-tamoxifen (TAM) and 5-fluorouracil (5-FU), but not doxorubicin (Dox), resulted in additive antitumor effects on endocrine-responsive breast cancer cells." | 7.76 | Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer. ( Kiniwa, M; Kurebayashi, J; Nukatsuka, M; Sonoo, H; Uchida, J, 2010) |
| "A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice." | 7.73 | Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. ( Bae, JY; Bae, YJ; Han, MR; Han, W; Hwang, KT; Hwang, SE; Kang, JJ; Kim, SW; Lee, JE; Lee, JH; Noh, DY; Shin, HJ, 2006) |
| "To study the value of adjuvant tamoxifen (TAM) in premenopausal women with oestrogen receptor (ER)-positive breast cancer who received adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) polychemotherapy." | 7.72 | Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer. ( Hou, YF; Li, HC; Lu, JS; Shao, ZM; Shen, KW; Shen, ZZ; Wen, XF; Wu, J, 2003) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 7.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "The effects of tamoxifen and 5-fluorouracil (5-FU) on the patterns of argyrophilic nucleolar organizer regions (AgNORs) in MCF7 human breast cancer cells were studied." | 7.69 | Title aggregation patterns of argyrophilic nucleolar organizer regions induced by 5-fluorouracil in the nuclei of MCF-7 human breast cancer cells. ( Furuya, Y; Nishihara, T; Saitoh, Y; Yamamoto, K, 1996) |
| "Women with HR+, HER2-negative operable breast cancer received capecitabine, 2000 mg/m(2) daily in divided doses for 14 days, followed by a 7-day rest period." | 6.79 | A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. ( Bellon, J; Brock, J; Come, SE; Golshan, M; Guo, H; Jeong, J; Krop, IE; Morganstern, D; Tolaney, SM; Winer, EP, 2014) |
| " Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 6.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
| "We examined if inclusion of a taxane and more prolonged preoperative chemotherapy improves pathologic complete response (pCR) rate in estrogen receptor (ER)-positive breast cancer compared with three to four courses of 5-fluorouracil, doxorubicin, cyclophosphamide (FAC)." | 6.22 | Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. ( Anderson, K; Andre, F; Buchholz, TA; Buzdar, AU; Frye, D; Gonzalez-Angulo, AM; Hess, KR; Hortobagyi, GN; Kau, SW; Kuerer, HM; Mazouni, C; Pusztai, L; Symmans, WF, 2007) |
| "The purpose of this study was to determine the relative efficacy of doxorubicin versus methotrexate in combination with intravenous cyclophosphamide and 5-fluorouracil (FAC versus CMF) as adjuvant chemotherapy for operable breast cancer." | 6.20 | Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a ( Albanell, J; Aranda, J; Campbell, J; Camps, C; Candel, MT; Carrato, A; Casado, A; Diaz-Rubio, E; Gonzalez, R; Lizon, J; Martin, M; Massuti, B; Munarriz, B; Sole-Calvo, A; Villar, A, 2003) |
| "Women with node-positive primary breast cancer were randomly assigned to receive tamoxifen (20 mg/d for 5 years) during (concurrent arm) or after (sequential arm) adjuvant chemotherapy." | 5.15 | Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. ( Bedognetti, D; Boccardo, F; Bruzzi, P; Del Mastro, L; Gardin, G; Monzeglio, C; Pastorino, S; Pronzato, P; Queirolo, P; Sertoli, MR; Siffredi, G; Taveggia, P; Venturini, M; Wang, E; Zanardi, E, 2011) |
| "Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies." | 5.15 | Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. ( Chen, DR; Chen, ST; Hsieh, CM; Huang, CS; Kuo, SH; Lu, YS; Tseng, LM; Wang, HC; Yeh, DC; Yeh, HT, 2011) |
| "International Breast Cancer Study Group Trial VIII compared cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for 6 cycles followed by endocrine therapy with goserelin with either modality alone in pre- and perimenopausal patients." | 5.13 | Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. ( Braye, S; Brown, RW; Castiglione-Gertsch, M; Coates, AS; Gelber, RD; Goldhirsch, A; Golouh, R; Grigolato, P; Gusterson, BA; Kovács, A; Maiorano, E; Mastropasqua, MG; Ohlschlegel, C; Perin, T; Pillay, K; Price, KN; Regan, MM; Rusca, T; Viale, G, 2008) |
| "The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, 500 mg/m2; mitoxantrone (Novantrone), 10 mg/m2; fluorouracil, 500 mg/m2 chemotherapy and ovarian ablation in premenopausal patients with node-positive breast cancer and conversely from the incorporation of CNF chemotherapy to adjuvant tamoxifen in node-positive postmenopausal patients." | 5.11 | Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. ( Adamou, A; Bafaloukos, D; Ekonomopoulos, T; Fountzilas, G; Georgoulias, V; Kalofonos, HP; Klouvas, G; Kosmidis, P; Koukouras, D; Kouvatseas, G; Kyriakou, K; Pavlidis, N; Pectasidis, D; Polychronis, A; Razis, E; Samantas, E; Skarlos, D; Stathopoulos, G; Zamboglou, N; Zombolas, V, 2004) |
| "In the International Breast Cancer Study Group (IBCSG) trial VII, 1212 postmenopausal patients with node-positive disease were randomized to receive tamoxifen for 5 years or tamoxifen plus three concurrent courses of cyclophosphamide, methotrexate and 5-fluorouracil ('classical' CMF) chemotherapy, either early, delayed or both." | 5.11 | Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Collins, J; Crivellari, D; Erzen, D; Forbes, J; Gelber, RD; Goldhirsch, A; Holmberg, S; Li, S; Lindtner, J; Murray, E; Pagani, O; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B; Veronesi, A, 2005) |
| "To compare the efficacy of chemotherapy versus that of tamoxifen plus ovarian suppression in pre-/perimenopausal estrogen receptor-positive patients with early breast cancer." | 5.09 | Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomi ( Aldrighetti, D; Amoroso, D; Boccardo, F; Bolognesi, A; Distante, V; Farris, A; Genta, F; Giai, M; Mesiti, M; Pacini, P; Romeo, D; Rubagotti, A; Sismondi, P, 2000) |
| "Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide." | 5.07 | Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study. ( Coltman, CA; Ellis, GK; Green, S; Hynes, HE; Livingston, RB; Rivkin, S; Schulman, S, 1991) |
| "Eighty-nine postmenopausal women with metastatic breast cancer, in whom estrogen receptors (ER) were positive or unknown, were treated on a controlled trial to determine the effectiveness of tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders." | 5.05 | Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial. ( Brodovsky, H; Catalano, RB; Creech, RH; Glick, JH; Holroyde, C; Torri, S; Varano, M, 1980) |
| " Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy." | 4.85 | Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. ( Guarneri, V, 2009) |
| "Our previous study indicated that concurrent administration of 4-OH-tamoxifen (TAM) and 5-fluorouracil (5-FU), but not doxorubicin (Dox), resulted in additive antitumor effects on endocrine-responsive breast cancer cells." | 3.76 | Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer. ( Kiniwa, M; Kurebayashi, J; Nukatsuka, M; Sonoo, H; Uchida, J, 2010) |
| "Thus, in women with advanced breast cancer excessive tumor cell burden and permanent drug resistance remain the major obstacles to obtaining complete remission and long-term disease free survival." | 3.75 | Chemotherapy of breast cancer: current views and results. ( Bonadonna, G; Valagussa, P, 1983) |
| "We included 199 patients with HER2+ breast cancer from three successive cohorts of neo-adjuvant chemotherapy on the basis of paclitaxel (Taxol) (P) administered weekly (w) or three weekly (3-w), followed by 5-fluorouracil (F), doxorubicin (A) or epirubicin (E), and cyclophosphamide (C)." | 3.74 | Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. ( Buzdar, AU; Dawood, SS; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hatzis, C; Hortobagyi, GN; Kuerer, HM; Mejia, JA; Peintinger, F; Pusztai, L; Symmans, WF, 2008) |
| "A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice." | 3.73 | Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. ( Bae, JY; Bae, YJ; Han, MR; Han, W; Hwang, KT; Hwang, SE; Kang, JJ; Kim, SW; Lee, JE; Lee, JH; Noh, DY; Shin, HJ, 2006) |
| "We investigated relapse-free (RFS), breast cancer-corrected (BCCS) and overall survival (OS) related to TP53 status in node-positive breast cancer patients that had received polychemotherapy [cyclophosphamide, methotrexate, 5-fluorouracil (CMF)] and/or endocrine therapy (tamoxifen)." | 3.73 | Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. ( Andersson, J; Bergh, J; Carlsson, G; Gustavsson, B; Holmberg, L; Inganäs, M; Klaar, S; Larsson, L; Nilsson, J; Ohd, J; Rudenstam, CM, 2005) |
| "We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil." | 3.73 | t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006) |
| "Hormone responsive breast cancer cell lines MCF-7 and T47D, and the ER- cell line MDA-231, were treated with either 4-hydroxy tamoxifen (4OHT) or arzoxifene during weekly courses of treatment with 5-fluorouracil (5-FU) or methotrexate (MTX)." | 3.72 | Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. ( Licun, W; Tannock, IF, 2003) |
| "To study the value of adjuvant tamoxifen (TAM) in premenopausal women with oestrogen receptor (ER)-positive breast cancer who received adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) polychemotherapy." | 3.72 | Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer. ( Hou, YF; Li, HC; Lu, JS; Shao, ZM; Shen, KW; Shen, ZZ; Wen, XF; Wu, J, 2003) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 3.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "The effects of tamoxifen and 5-fluorouracil (5-FU) on the patterns of argyrophilic nucleolar organizer regions (AgNORs) in MCF7 human breast cancer cells were studied." | 3.69 | Title aggregation patterns of argyrophilic nucleolar organizer regions induced by 5-fluorouracil in the nuclei of MCF-7 human breast cancer cells. ( Furuya, Y; Nishihara, T; Saitoh, Y; Yamamoto, K, 1996) |
| "Sixty-nine patients with locally advanced breast cancer were given induction chemotherapy with doxorubicin and cyclophosphamide (day 1) followed by methotrexate and 5-Fu (day 8)." | 3.69 | Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer. ( Malmström, P; Sjövall, MP, 1997) |
| "One hundred and ten patients with stage IV breast cancer were treated with five-drug chemotherapy consisting of prednisone, cyclophosphamide, 5-fluorouracil, methotrexate, and vincristine." | 3.66 | Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. ( Manni, A; Pearson, OH; Trujillo, JE, 1980) |
| "Women with HR+, HER2-negative operable breast cancer received capecitabine, 2000 mg/m(2) daily in divided doses for 14 days, followed by a 7-day rest period." | 2.79 | A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. ( Bellon, J; Brock, J; Come, SE; Golshan, M; Guo, H; Jeong, J; Krop, IE; Morganstern, D; Tolaney, SM; Winer, EP, 2014) |
| "In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment." | 2.74 | Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. ( Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Forbes, JF; Gelber, RD; Gelber, S; Goldhirsch, A; Holmberg, SB; Lindtner, J; Murray, E; Pagani, O; Price, KN; Simoncini, E; Thürlimann, B, 2009) |
| " Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 2.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
| "In conclusion, in a group of metastatic breast cancer patients, treated routinely by systemic therapies it was found, that the use of higher cut-off point for EGF-R positivity can improve the prediction of endocrine sensitivity." | 2.69 | Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. ( Branković-Magić, MV; Mitrovic, LB; Nesković-Konstantinović, ZB; Nikolić-Vukosavljević, DB; Spuzić, I, 2000) |
| " 5FU was given as a 24-hour infusion at a dosage of 4 g/m2 and oral leucovorin at a dosage of 50 mg every 6 hours for four doses, starting with the infusion of 5FU." | 2.68 | Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. ( Atkins, JN; Case, LD; Grote, T; McFarland, J; Muss, HB; Richards, F, 1996) |
| "In patients of 70 years and under with prostate cancer resistant to androgen-deprivation therapy and who still have good performance status, ECF chemotherapy can achieve useful remissions." | 2.68 | A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. ( Chao, D; Harland, SJ; von Schlippe, M, 1997) |
| "Breast cancer is the most common malignancy among American women." | 2.41 | Operable breast cancer. ( Cianfrocca, M; Goldstein, LJ, 2001) |
| "In conclusion, patients with breast cancer may experience changes in HR status, HER2 status and tumor phenotype after NCT." | 1.42 | Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. ( Chen, S; Di, GH; Jiang, YZ; Jin, X; Shao, ZM; Yu, KD, 2015) |
| "The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown." | 1.39 | Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. ( Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P, 2013) |
| "From 1998 to 2006, 370 primary breast cancer patients underwent curative surgical treatment after NAC containing both anthracycline and taxane at the National Cancer Center Hospital." | 1.35 | Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. ( Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C, 2009) |
| "As 5-fluorouracil (5-FU) has been known to show clinically antitumor effects against both breast and stomach carcinomas." | 1.29 | [Effect of medroxyprogesterone acetate on the anticellular activity of 5-fluorouracil against human breast and stomach cancer cells]. ( Gomi, K; Horiuchi, R; Ishida, H; Okabe, M, 1993) |
| "It is generally accepted that breast cancer with positive steroid receptors has a better prognosis than with negative receptors." | 1.28 | [Prognostic and therapeutic significance of steroid receptors in invasive breast cancer]. ( Hochuli, E; Rageth, JC; Unger, C; Wyss, P, 1992) |
| "As a prerequisite four human breast cancer cell lines (MDA-MB-231, MCF-7, T-47-D and ZR-75-1) were characterized with regard to oestrogen and progesterone receptor content, modal chromosome number and proliferation kinetics depending on the number of passages in culture." | 1.28 | Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. ( Bernhardt, G; Birnböck, H; Reile, H; Schönenberger, H; Spruss, T, 1992) |
| "Case report of a 45-year-old woman with breast cancer who underwent mastectomy with axillary lymphonodectomy and radiation therapy." | 1.28 | [Ablative hormone therapy and chemotherapy of metastatic breast cancer]. ( Blaschke, U; Gerber, B; Kasch, R, 1989) |
| "Chemotherapy results in metastatic breast cancer reached a plateau: Remission rate and duration are nearly equivalent for several regimens but not equitoxic." | 1.27 | [Vinblastine, 5-fluorouracil and prednisone (VFP) as "second-line" chemotherapy. Contribution to the problem of optimal therapy sequence in metastasizing breast carcinoma]. ( Hartlapp, JH; Illiger, HJ; Peiss, J; Vaupel, HA, 1983) |
| "In human breast cancer, about 90% of unresponsive tumors and 60-80% of tumors responsive to endocrine therapy can be predicted by receptor measurement." | 1.27 | [Breast cancer--topics from basic research]. ( Kuroda, H; Matsumoto, K; Takeyama, M, 1984) |
| "Four human breast carcinoma strains serially transplanted into nude mice were used for the experimental chemotherapy and combination chemoendocrine therapy." | 1.27 | [Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice]. ( Koh, J, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (19.72) | 18.7374 |
| 1990's | 13 (18.31) | 18.2507 |
| 2000's | 33 (46.48) | 29.6817 |
| 2010's | 11 (15.49) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Lauro, L | 1 |
| Vici, P | 1 |
| Del Medico, P | 1 |
| Laudadio, L | 1 |
| Tomao, S | 1 |
| Giannarelli, D | 1 |
| Pizzuti, L | 1 |
| Sergi, D | 1 |
| Barba, M | 1 |
| Maugeri-Saccà, M | 1 |
| Tolaney, SM | 1 |
| Jeong, J | 1 |
| Guo, H | 1 |
| Brock, J | 1 |
| Morganstern, D | 1 |
| Come, SE | 1 |
| Golshan, M | 1 |
| Bellon, J | 1 |
| Winer, EP | 1 |
| Krop, IE | 1 |
| Abdel-Fatah, TM | 1 |
| McArdle, SE | 1 |
| Johnson, C | 1 |
| Moseley, PM | 1 |
| Ball, GR | 1 |
| Pockley, AG | 1 |
| Ellis, IO | 1 |
| Rees, RC | 1 |
| Chan, SY | 1 |
| Jin, X | 1 |
| Jiang, YZ | 1 |
| Chen, S | 1 |
| Yu, KD | 1 |
| Shao, ZM | 2 |
| Di, GH | 1 |
| Peintinger, F | 1 |
| Buzdar, AU | 2 |
| Kuerer, HM | 2 |
| Mejia, JA | 1 |
| Hatzis, C | 1 |
| Gonzalez-Angulo, AM | 2 |
| Pusztai, L | 2 |
| Esteva, FJ | 1 |
| Dawood, SS | 1 |
| Green, MC | 1 |
| Hortobagyi, GN | 2 |
| Symmans, WF | 2 |
| Pagani, O | 2 |
| Gelber, S | 1 |
| Simoncini, E | 2 |
| Castiglione-Gertsch, M | 3 |
| Price, KN | 3 |
| Gelber, RD | 3 |
| Holmberg, SB | 1 |
| Crivellari, D | 2 |
| Collins, J | 2 |
| Lindtner, J | 2 |
| Thürlimann, B | 2 |
| Fey, MF | 1 |
| Murray, E | 2 |
| Forbes, JF | 1 |
| Coates, AS | 3 |
| Goldhirsch, A | 3 |
| Park, D | 1 |
| Kåresen, R | 1 |
| Naume, B | 1 |
| Synnestvedt, M | 1 |
| Beraki, E | 1 |
| Sauer, T | 1 |
| Kurebayashi, J | 1 |
| Nukatsuka, M | 1 |
| Sonoo, H | 1 |
| Uchida, J | 1 |
| Kiniwa, M | 1 |
| Guarneri, V | 1 |
| Lu, YS | 1 |
| Chen, DR | 1 |
| Tseng, LM | 1 |
| Yeh, DC | 1 |
| Chen, ST | 1 |
| Hsieh, CM | 1 |
| Wang, HC | 1 |
| Yeh, HT | 1 |
| Kuo, SH | 1 |
| Huang, CS | 1 |
| Petit, T | 1 |
| Wilt, M | 1 |
| Velten, M | 1 |
| Rodier, JF | 1 |
| Fricker, JP | 1 |
| Dufour, P | 1 |
| Ghnassia, JP | 1 |
| Kawabata, R | 1 |
| Oie, S | 1 |
| Oka, T | 1 |
| Takahashi, M | 1 |
| Kanayama, H | 1 |
| Itoh, K | 1 |
| Tanaka, T | 1 |
| Ikeda, H | 1 |
| Taira, N | 1 |
| Nogami, T | 1 |
| Shien, K | 1 |
| Okada, M | 1 |
| Shien, T | 2 |
| Doihara, H | 1 |
| Miyoshi, S | 1 |
| Bedognetti, D | 1 |
| Sertoli, MR | 1 |
| Pronzato, P | 1 |
| Del Mastro, L | 1 |
| Venturini, M | 1 |
| Taveggia, P | 1 |
| Zanardi, E | 1 |
| Siffredi, G | 1 |
| Pastorino, S | 1 |
| Queirolo, P | 1 |
| Gardin, G | 1 |
| Wang, E | 1 |
| Monzeglio, C | 1 |
| Boccardo, F | 2 |
| Bruzzi, P | 1 |
| Koh, J | 2 |
| Kubota, T | 1 |
| Migita, T | 1 |
| Abe, S | 1 |
| Hashimoto, M | 1 |
| Hosoda, Y | 1 |
| Kitajima, M | 1 |
| Martin, M | 1 |
| Villar, A | 1 |
| Sole-Calvo, A | 1 |
| Gonzalez, R | 1 |
| Massuti, B | 1 |
| Lizon, J | 1 |
| Camps, C | 1 |
| Carrato, A | 1 |
| Casado, A | 1 |
| Candel, MT | 1 |
| Albanell, J | 1 |
| Aranda, J | 1 |
| Munarriz, B | 1 |
| Campbell, J | 1 |
| Diaz-Rubio, E | 1 |
| Li, HC | 1 |
| Wen, XF | 1 |
| Hou, YF | 1 |
| Shen, KW | 1 |
| Wu, J | 1 |
| Lu, JS | 1 |
| Shen, ZZ | 1 |
| Licun, W | 1 |
| Tannock, IF | 1 |
| Schüll, B | 1 |
| Scheithauer, W | 1 |
| Kornek, GV | 1 |
| Fountzilas, G | 2 |
| Stathopoulos, G | 1 |
| Kouvatseas, G | 1 |
| Polychronis, A | 1 |
| Klouvas, G | 1 |
| Samantas, E | 2 |
| Zamboglou, N | 1 |
| Kyriakou, K | 1 |
| Adamou, A | 1 |
| Pectasidis, D | 1 |
| Ekonomopoulos, T | 1 |
| Kalofonos, HP | 2 |
| Bafaloukos, D | 2 |
| Georgoulias, V | 1 |
| Razis, E | 1 |
| Koukouras, D | 1 |
| Zombolas, V | 1 |
| Kosmidis, P | 1 |
| Skarlos, D | 2 |
| Pavlidis, N | 1 |
| Birtle, AJ | 1 |
| Newby, JC | 1 |
| Harland, SJ | 2 |
| Filipits, M | 1 |
| Pohl, G | 1 |
| Rudas, M | 1 |
| Dietze, O | 1 |
| Lax, S | 1 |
| Grill, R | 1 |
| Pirker, R | 1 |
| Zielinski, CC | 1 |
| Hausmaninger, H | 1 |
| Kubista, E | 1 |
| Samonigg, H | 1 |
| Jakesz, R | 1 |
| Andersson, J | 1 |
| Larsson, L | 1 |
| Klaar, S | 1 |
| Holmberg, L | 1 |
| Nilsson, J | 1 |
| Inganäs, M | 1 |
| Carlsson, G | 1 |
| Ohd, J | 1 |
| Rudenstam, CM | 2 |
| Gustavsson, B | 1 |
| Bergh, J | 2 |
| Colleoni, M | 1 |
| Li, S | 1 |
| Forbes, J | 1 |
| Erzen, D | 1 |
| Holmberg, S | 1 |
| Veronesi, A | 1 |
| Rodney, A | 1 |
| Dieringer, P | 1 |
| Mathew, P | 1 |
| Jonasch, E | 1 |
| Tannir, N | 1 |
| Pagliaro, LC | 1 |
| Han, W | 1 |
| Han, MR | 1 |
| Kang, JJ | 1 |
| Bae, JY | 1 |
| Lee, JH | 1 |
| Bae, YJ | 1 |
| Lee, JE | 1 |
| Shin, HJ | 1 |
| Hwang, KT | 1 |
| Hwang, SE | 1 |
| Kim, SW | 1 |
| Noh, DY | 1 |
| Ferrero, JM | 1 |
| Chamorey, E | 1 |
| Oudard, S | 1 |
| Dides, S | 1 |
| Lesbats, G | 1 |
| Cavaglione, G | 1 |
| Nouyrigat, P | 1 |
| Foa, C | 1 |
| Kaphan, R | 1 |
| Huang, CJ | 1 |
| Hou, MF | 1 |
| Lin, SD | 1 |
| Chuang, HY | 1 |
| Huang, MY | 1 |
| Fu, OY | 1 |
| Lian, SL | 1 |
| Kolodziej, M | 1 |
| Neubauer, MA | 1 |
| Rousey, SR | 1 |
| Pluenneke, RE | 1 |
| Perrine, G | 1 |
| Mull, S | 1 |
| Boehm, KA | 1 |
| Ilegbodu, D | 1 |
| Asmar, L | 1 |
| Ejlertsen, B | 1 |
| Mouridsen, HT | 1 |
| Jensen, MB | 1 |
| Bengtsson, NO | 1 |
| Cold, S | 1 |
| Edlund, P | 1 |
| Ewertz, M | 1 |
| de Graaf, PW | 1 |
| Kamby, C | 1 |
| Nielsen, DL | 1 |
| Mazouni, C | 1 |
| Kau, SW | 1 |
| Frye, D | 1 |
| Andre, F | 1 |
| Buchholz, TA | 1 |
| Anderson, K | 1 |
| Hess, KR | 1 |
| Sahin, FI | 1 |
| Yilmaz, Z | 1 |
| Karakuş, S | 1 |
| Boğa, S | 1 |
| Akçali, Z | 1 |
| DemIrhan, B | 1 |
| Dafni, U | 1 |
| Gogas, H | 1 |
| Linardou, H | 1 |
| Briasoulis, E | 1 |
| Pectasides, D | 1 |
| Stathopoulos, GP | 1 |
| Karina, M | 1 |
| Papadimitriou, C | 1 |
| Pisanidis, N | 1 |
| Papakostas, P | 1 |
| Markopoulos, C | 1 |
| Tzorakoeleftherakis, E | 1 |
| Dimitrakakis, K | 1 |
| Makrantonakis, P | 1 |
| Xiros, N | 1 |
| Polichronis, A | 1 |
| Varthalitis, I | 1 |
| Karanikiotis, C | 1 |
| Dimopoulos, AM | 1 |
| Gluz, O | 1 |
| Nitz, UA | 1 |
| Harbeck, N | 1 |
| Ting, E | 1 |
| Kates, R | 1 |
| Herr, A | 1 |
| Lindemann, W | 1 |
| Jackisch, C | 1 |
| Berdel, WE | 1 |
| Kirchner, H | 1 |
| Metzner, B | 1 |
| Werner, F | 1 |
| Schütt, G | 1 |
| Frick, M | 1 |
| Poremba, C | 1 |
| Diallo-Danebrock, R | 1 |
| Mohrmann, S | 1 |
| Shimizu, C | 1 |
| Seki, K | 1 |
| Shibata, T | 1 |
| Hojo, T | 1 |
| Ando, M | 1 |
| Kohno, T | 1 |
| Katsumata, N | 1 |
| Akashi-Tanaka, S | 1 |
| Kinoshita, T | 1 |
| Fujiwara, Y | 1 |
| Viale, G | 1 |
| Regan, MM | 1 |
| Maiorano, E | 1 |
| Mastropasqua, MG | 1 |
| Golouh, R | 1 |
| Perin, T | 1 |
| Brown, RW | 1 |
| Kovács, A | 1 |
| Pillay, K | 1 |
| Ohlschlegel, C | 1 |
| Braye, S | 1 |
| Grigolato, P | 1 |
| Rusca, T | 1 |
| Gusterson, BA | 1 |
| Manni, A | 1 |
| Trujillo, JE | 1 |
| Pearson, OH | 1 |
| Preda, F | 1 |
| Oriana, S | 1 |
| Perozziello, F | 1 |
| Botte, G | 1 |
| Lo Russo, V | 1 |
| Bonadonna, G | 1 |
| Valagussa, P | 1 |
| Illiger, HJ | 1 |
| Peiss, J | 1 |
| Vaupel, HA | 1 |
| Hartlapp, JH | 1 |
| Matsumoto, K | 1 |
| Kuroda, H | 1 |
| Takeyama, M | 1 |
| Kiang, DT | 1 |
| Kennedy, BJ | 1 |
| Glick, JH | 1 |
| Creech, RH | 1 |
| Torri, S | 1 |
| Holroyde, C | 1 |
| Brodovsky, H | 1 |
| Catalano, RB | 1 |
| Varano, M | 1 |
| Drago, JR | 2 |
| Goldman, LB | 1 |
| Gershwin, ME | 2 |
| Möbus, V | 1 |
| Paula, J | 1 |
| Beck, T | 1 |
| Crombach, G | 1 |
| Kreienberg, R | 1 |
| Ishida, H | 1 |
| Okabe, M | 1 |
| Gomi, K | 1 |
| Horiuchi, R | 1 |
| Atkins, JN | 1 |
| Muss, HB | 1 |
| Case, LD | 1 |
| Richards, F | 1 |
| Grote, T | 1 |
| McFarland, J | 1 |
| Nishihara, T | 1 |
| Furuya, Y | 1 |
| Yamamoto, K | 1 |
| Saitoh, Y | 1 |
| Sjövall, MP | 1 |
| Malmström, P | 1 |
| Chao, D | 1 |
| von Schlippe, M | 1 |
| Berlin, JD | 1 |
| Propert, KJ | 1 |
| Trump, D | 1 |
| Wilding, G | 1 |
| Hudes, G | 1 |
| Glick, J | 1 |
| Burch, P | 1 |
| Keller, A | 1 |
| Loehrer, P | 1 |
| Pegram, M | 1 |
| Hsu, S | 1 |
| Lewis, G | 1 |
| Pietras, R | 1 |
| Beryt, M | 1 |
| Sliwkowski, M | 1 |
| Coombs, D | 1 |
| Baly, D | 1 |
| Kabbinavar, F | 1 |
| Slamon, D | 1 |
| Cameron, DA | 1 |
| Gregory, WM | 1 |
| Bowman, A | 1 |
| Anderson, ED | 1 |
| Levack, P | 1 |
| Forouhi, P | 1 |
| Leonard, RC | 1 |
| Rubagotti, A | 1 |
| Amoroso, D | 1 |
| Mesiti, M | 1 |
| Romeo, D | 1 |
| Sismondi, P | 1 |
| Giai, M | 1 |
| Genta, F | 1 |
| Pacini, P | 1 |
| Distante, V | 1 |
| Bolognesi, A | 1 |
| Aldrighetti, D | 1 |
| Farris, A | 1 |
| Nesković-Konstantinović, ZB | 1 |
| Nikolić-Vukosavljević, DB | 1 |
| Branković-Magić, MV | 1 |
| Mitrovic, LB | 1 |
| Spuzić, I | 1 |
| Hartman, AR | 1 |
| Fleming, GF | 1 |
| Dillon, JJ | 1 |
| Di Leo, A | 1 |
| Buyse, M | 1 |
| Elias, AD | 1 |
| Ibrahim, J | 1 |
| Richardson, P | 1 |
| Avigan, D | 1 |
| Joyce, R | 1 |
| Reich, E | 1 |
| McCauley, M | 1 |
| Wheeler, C | 1 |
| Frei, E | 1 |
| Cianfrocca, M | 1 |
| Goldstein, LJ | 1 |
| Maurer, RE | 1 |
| Eckels, D | 1 |
| Palmer, JM | 1 |
| Wyss, P | 1 |
| Rageth, JC | 1 |
| Unger, C | 1 |
| Hochuli, E | 1 |
| Bernhardt, G | 1 |
| Reile, H | 1 |
| Birnböck, H | 1 |
| Spruss, T | 1 |
| Schönenberger, H | 1 |
| Ellis, GK | 1 |
| Green, S | 1 |
| Schulman, S | 1 |
| Coltman, CA | 1 |
| Hynes, HE | 1 |
| Rivkin, S | 1 |
| Livingston, RB | 1 |
| Fisher, B | 1 |
| Redmond, C | 1 |
| Legault-Poisson, S | 1 |
| Dimitrov, NV | 1 |
| Brown, AM | 1 |
| Wickerham, DL | 1 |
| Wolmark, N | 1 |
| Margolese, RG | 1 |
| Bowman, D | 1 |
| Glass, AG | 1 |
| Merkle, E | 1 |
| Seidl, C | 1 |
| Fuchs, U | 1 |
| Sauerbrei, W | 1 |
| Wirtz, PM | 1 |
| Kasch, R | 1 |
| Gerber, B | 1 |
| Blaschke, U | 1 |
| Ueki, H | 1 |
| Semiglazov, VF | 1 |
| Moiseenko, VM | 1 |
| Ivanova, OA | 1 |
| Servadio, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Preoperative Capecitabine in Women With Operable Breast Cancer[NCT00148720] | Phase 2 | 80 participants (Anticipated) | Interventional | 2004-09-30 | Terminated (stopped due to Slow accrual) | ||
| Adjuvant Therapy for Post/Perimenopausal Patients With Node Positive Breast Cancer Who Are Suitable for Endocrine Therapy Alone.[NCT00002529] | Phase 3 | 452 participants (Actual) | Interventional | 1993-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluorouracil and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2003 |
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compound | 2007 |
Chemotherapy of breast cancer: current views and results.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1983 |
Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2001 |
Operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Thera | 2001 |
27 trials available for fluorouracil and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2014 |
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2009 |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplat | 2011 |
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Brea | 2011 |
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2003 |
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2004 |
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Co | 2005 |
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.
Topics: Administration, Oral; Aged; Androgens; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2006 |
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2006 |
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2006 |
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compound | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2008 |
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinom | 2008 |
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2008 |
Chemotherapy of breast cancer: current views and results.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1983 |
Chemoendocrine therapy in advanced breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide | 1981 |
Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr | 1980 |
Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association.
Topics: Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Leucovori | 1996 |
A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1997 |
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; H | 1998 |
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomi
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2000 |
Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2000 |
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma; Com | 2002 |
Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1991 |
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Proje
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubici | 1990 |
[Prospective randomized study of the efficacy of adjuvant hormone therapy in patients with breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1986 |
41 other studies available for fluorouracil and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inh | 2013 |
HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2014 |
Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined | 2015 |
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
The prognostic impact of occult nodal metastasis in early breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bone Marrow; | 2009 |
Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Eva | 2010 |
Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2010 |
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug E | 2011 |
Quantitative analysis of the enzymes associated with 5-fluorouracil metabolism in prostate cancer biopsies.
Topics: Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression; Humans; Lasers; Male; Microdissec | 2011 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2011 |
UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction.
Topics: Alkaloids; Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cyclophosphamide; Do | 2002 |
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2003 |
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; | 2003 |
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2003 |
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; E | 2004 |
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Austria; Bio | 2005 |
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2005 |
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2006 |
Comparison of local recurrence and distant metastases between breast cancer patients after postmastectomy radiotherapy with and without immediate TRAM flap reconstruction.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2006 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2006 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, C | 1980 |
Clinical response to chemotherapy and hormone therapy as first treatment after therapeutic ovariectomy in advanced breast cancer patients.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Castration; Cyclophosphamide; Dexamethasone; Doxorub | 1982 |
[Vinblastine, 5-fluorouracil and prednisone (VFP) as "second-line" chemotherapy. Contribution to the problem of optimal therapy sequence in metastasizing breast carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1983 |
[Breast cancer--topics from basic research].
Topics: Animals; Breast Neoplasms; Female; Fluorouracil; Humans; Melphalan; Mice; Neoplasms, Hormone-Depende | 1984 |
Evaluation of nonhormonal cytotoxic chemotherapy in the Nb rat prostate adenocarcinoma: autonomous tumor (18-Pr and 13-Pr).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Ev | 1980 |
[Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy in metastatic breast cancer].
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 1993 |
[Effect of medroxyprogesterone acetate on the anticellular activity of 5-fluorouracil against human breast and stomach cancer cells].
Topics: Breast Neoplasms; Cell Division; Drug Synergism; Estrogens; Female; Fluorouracil; Humans; Medroxypro | 1993 |
Title aggregation patterns of argyrophilic nucleolar organizer regions induced by 5-fluorouracil in the nuclei of MCF-7 human breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Aggregation | 1996 |
Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 1997 |
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal | 1999 |
Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Chemotherapy, A | 2000 |
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemoth | 2002 |
The effect of 5-fluorouracil and adriamycin on heterotransplantation of Noble rat prostatic tumors in congenitally athymic (nude) mice.
Topics: Adenocarcinoma; Animals; Doxorubicin; Fluorouracil; Male; Mice; Mice, Nude; Neoplasm Transplantation | 1979 |
[Prognostic and therapeutic significance of steroid receptors in invasive breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Co | 1992 |
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ce | 1992 |
[Adjuvant chemotherapy of breast cancer with the CMFV protocol].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
[Ablative hormone therapy and chemotherapy of metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltr | 1989 |
[Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cyclophosphamide; Doxorubicin; Female; | 1988 |
[Synergistic effect of cell kinetics-directed chemo-endocrine therapy on experimental mammary tumors].
Topics: Androgens; Animals; Cell Cycle; Combined Modality Therapy; Drug Administration Schedule; Drug Therap | 1987 |
The case for early combined hormonal and cytostatic treatment for metastatic prostatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Diethyl | 1987 |